Is the short posterior stabilization by TLIF and cages a good way for a correct spinal alignment in the de novo scoliosis? A case report

De novo scoliosis is becoming one of the most prevalent findings in the aging spine, and this condition is associated not only with severe back or leg symptoms but also with complicated surgical outcomes. The most common surgery is a posterior spinal fusion with metal implants and bone graft (from the pelvis or the bone bank), with or without decompression of the nerve roots. Sometimes the surgery may need to be performed anteriorly (from the front of the spine) for better stability, correction, and healing. After 1 years of follow, up we presented a case report of a 74 year old man treated for De Novo Scoliosis with a spinal short posterior stabilization, TLIF and Cages

A multi-society position paper on the prevention and management of nosocomial and severe infections: the Italian Society for Infectious Diseases, the Italian Multidisciplinary Society of Hospital Infections, the Italian Society of Chemotherapy, the Italian Society of Respiratory Medicine, the Italian Society of Clinical Microbiology, the Italian Society of Microbiology, and GISIG (Italian Study Group on Severe Infections)

Amulti-society position paper on the prevention and management of nosocomial and severe infections: the Italian Society for Infectious Diseases, the Italian Multidisciplinary Society of Hospital Infections, the Italian Society of Chemotherapy, the Italian Society of Respiratory Medicine, the Italian Society of Clinical Microbiology, the Italian Society of Microbiology, and GISIG (Italian Study Group on Severe Infections

Le infezioni catetere vascolare correlate: risultati di tre anni di sorveglianza (2001-2003)

n/

Real life turnaround time of blood cultures in the clinical microbiology laboratory: results of the first Italian survey, May 2015

Background and aims: Blood culture (BC) results are essential to guide antimicrobial chemotherapy for patients with sepsis. However, BC is a time-consuming exam, which can take several days. Reducing BCs turn around time (TAT) could impact on multiple outcome parameters and TAT monitoring is an important tool for measurement of microbiology laboratory performance. The aim of this study was to provide an overview of BC TATs among Italian microbiology laboratories. Materials and methods: Five laboratories collected and recorded, for a month period, date and time of the BC processing events. Cumulative TATs were analysed using the GraphPad software. Results: Participating laboratories reported data from 302 sepsis episodes. The median time from when the BC system produced a positive signal until Gram-stain results were reported was 7.6 hours. A rapid molecular identification and antimicrobial susceptibility testing (AST) was performed in 26.5% of BCs. Mean TAT for identification report was significantly lower when a molecular approach was adopted (12 vs. 28.7 hours, P<0.001). Similarly, results of the molecular AST were obtained more than 24 hours in advance compared with phenotypic AST (mean 13.2 vs. 47.6, P<0.001). TATs from BC positivity of laboratories opened 7 days/week were not significantly lower than those of laboratories opened 6 days/week. Conclusions: BC is a time-consuming exam, however, molecular identification and AST methods can drastically reduce time to results. The lack of difference between TATs observed for laboratories working 7 days/week and 6 days/week, coupled with a high rate of BCs turning positive during the night enable to conclude that the most urgent measure to reduce TATs is the expansion of laboratory regular duty hours

Short-, mid- and long-term efficacy of dupilumab in moderate to severe atopic dermatitis: a real life multicenter Italian study on 2576 patients

Background: The efficacy and safety of dupilumab in atopic dermatitis (AD) have been defined in clinical trials but limited real-world evidence on long term treatment outcomes are currently available to inform clinical decisions. Objectives: to describe long-term effectiveness and safety of dupilumab up to 48 months in patients with moderate-to-severe AD. Methods: a multicenter, retrospective, dynamic cohort study was conducted to assess long term effectiveness and safety of dupilumab in patients with moderate to severe AD in a real-world setting. Predictors of minimal disease activity (MDA) optimal treatment target criteria (defined as the simultaneous achievement of EASI90, itch NRS score ≤1, sleep NRS score ≤1 and DLQI ≤1) were investigated. Results: 2576 patients were enrolled from June 2018 to July 2022. MDA optimal treatment target criteria were achieved by 506 (21.91%), 769 (40.63%), 628 (50.36%), 330 (55.37%) and 58 (54.72%) of those that reached 4, 12, 24, 36 and 48 months of follow-up, respectively. Logistic regression revealed a negative effect on MDA achievement for conjunctivitis and food allergy at all timepoints. Adverse events (AE) were mild and were observed in 373 (15.78%), 166 (7.02%), 83 (6.43%), 27 (4.50%) and 5 (4.55%) of those that reached 4, 12, 24, 36 and 48 months of follow-up. Conjunctivitis was the most frequently reported AE during the available follow-up. AE led to treatment discontinuation in <1% of patients during the evaluated time periods. Conclusion: High long-term effectiveness and safety of dupilumab were confirmed in this dynamic cohort of patients with moderate to severe AD, regardless of clinical phenotype and course at baseline. Further research will be needed to investigate the effect of Th2 comorbidities and disease duration on the response to dupilumab and other newer therapeutics for AD

The role of immune suppression in COVID-19 hospitalization: clinical and epidemiological trends over three years of SARS-CoV-2 epidemic

Specific immune suppression types have been associated with a greater risk of severe COVID-19 disease and death. We analyzed data from patients >17 years that were hospitalized for COVID-19 at the “Fondazione IRCCS Ca′ Granda Ospedale Maggiore Policlinico” in Milan (Lombardy, Northern Italy). The study included 1727 SARS-CoV-2-positive patients (1,131 males, median age of 65 years) hospitalized between February 2020 and November 2022. Of these, 321 (18.6%, CI: 16.8–20.4%) had at least one condition defining immune suppression. Immune suppressed subjects were more likely to have other co-morbidities (80.4% vs. 69.8%, p < 0.001) and be vaccinated (37% vs. 12.7%, p < 0.001). We evaluated the contribution of immune suppression to hospitalization during the various stages of the epidemic and investigated whether immune suppression contributed to severe outcomes and death, also considering the vaccination status of the patients. The proportion of immune suppressed patients among all hospitalizations (initially stable at <20%) started to increase around December 2021, and remained high (30–50%). This change coincided with an increase in the proportions of older patients and patients with co-morbidities and with a decrease in the proportion of patients with severe outcomes. Vaccinated patients showed a lower proportion of severe outcomes; among non-vaccinated patients, severe outcomes were more common in immune suppressed individuals. Immune suppression was a significant predictor of severe outcomes, after adjusting for age, sex, co-morbidities, period of hospitalization, and vaccination status (OR: 1.64; 95% CI: 1.23–2.19), while vaccination was a protective factor (OR: 0.31; 95% IC: 0.20–0.47). However, after November 2021, differences in disease outcomes between vaccinated and non-vaccinated groups (for both immune suppressed and immune competent subjects) disappeared. Since December 2021, the spread of the less virulent Omicron variant and an overall higher level of induced and/or natural immunity likely contributed to the observed shift in hospitalized patient characteristics. Nonetheless, vaccination against SARS-CoV-2, likely in combination with naturally acquired immunity, effectively reduced severe outcomes in both immune competent (73.9% vs. 48.2%, p < 0.001) and immune suppressed (66.4% vs. 35.2%, p < 0.001) patients, confirming previous observations about the value of the vaccine in preventing serious disease

The answer of the Bacteriology Laboratory to new clinical needs. Rapid sepsis diagnotics at the Novara hospital

Faster microbiological responses are increasingly necessary in modern medicine and the Laboratory of Microbiology must be equipped in this sense. New instrumentation and, above all, a new approach by the Clinical Microbiologist that puts a focus on the real needs of the patient before the microbiological may allow for significantly improving the TAT of these diagnostics. The use of both new methodologies, new tools and revisited old technologies may mean less these days as it was obtained at the Laboratory of Microbiology and Virology of Novara, where the combined use of molecular biology techniques, and mass spectrometry techniques rapid growth have allowed for more than 36 hours to shorten the response time by positivization of blood cultures. Such an approach allows an important support to the clinician with obvious benefits for the patient

Identification using Matrix-Assisted Laser Desorption Ionization Time-Of-Flight Mass Spectrometry: Preliminar Data

Bacterial identification is usually allowed analyzing the phenotypic and biochemical topics of microorganisms. The traditional methods of identification require about 18-24 hours and are expensive. Matrix-Assisted Laser Desorption Ionization Time-Of-Flight Mass Spectrometry (MALDI-TOF MS) allows the identification of bacteria in few minutes. We consider 459 bacterial strains that were identified both with MALDI TOF MS and VITEK-2. The percentage of concordance in every group of bacteria was more than 99%, at genus level were more than 94% and at species level was more than 92%. These preliminary data show that MALDI-TOF MS allows a rapid and precise microorganism identification

Hospital epidemiology and antibiotic resistance in clinical isolates of Enterobacter cloacae

In thIe latter years Enterobacter cloacae has been counted as a very important occasional pathogen, above all in causing hospital infections.The micro-organism’s interesting increases because of its high resistance in vitro to many antimicrobial agents. For this reason it would be possible to find out others resistance mutant phenotypes. The results (2000-2001 and the first six months of 2002), carried out 341 isolated samples from hospital patients, show that the percentage of these E. cloacae is little more than 1%, increasing prevalence of patients belonging to General Surgery and Intensive Care Unit. The susceptible tests suggest (without important differences during the whole year) that most of the clinical isolates have moderate or high level resistance to various antimicrobial agents (penicillins, cephalosporins, aminoglycosides, quinolones, monobactam) and almost all were susceptible to amikacin, carbapenems (imipenem) and trimethoprim/sulfmamethoxazolo. Always regarding the resistance of these pathogens, it was possible to find out some phenotypes, and one of these, among 172 isolates belonging to Intensive Care Unit, was a particular multiresistance phenotype. The VITEK ESßL detection test and the conventional double disk synergy test for detection of ESßL find out some phenotypes showing expression of stably derepressed beta-lactamase

Phylogenetic relationships, virulence factors and Rep-PCR epidemiological analysis of E. coli from human sources

The potential of Escherichia coli to cause of extra-intestinal infections was studied on a group of 94 clinical isolates. In this work, 32 E. coli isolates from urinary tract infections, 25 from bacteraemia, 12 from low respiratory tract infections, and 25 from the normal commensal flora were characterized for the phylogenetic type, the virulence factors (VFs) carriage and the Rep-PCR clonal composition.The B2 phylogenetic type was predominant among the urinary isolates (59%), the B2 and D strains among the haematic isolates (32% and 32%).The A phylogenetic type was predominant among the commensal and the respiratory isolates (52% and 58% respectively).The distribution of the B2 type strains among the urinary isolates and of the D type strains among the faecal isolates was suggesting a urinary-origin for the B2 phylogenetic type isolates found in the blood and a direct faecal derivation for the haematic isolates with D phylogenetic type.Twenty-nine VFs were analyzed.The B2 and D type strains carried a higher burden of VFs than the A and B1 phylogenetic type strains (average of VFs/strain = 8 vs 3). Some of the VFs were homogeneously distributed among the phylogenetic types (fimH, iutA, fyuA, traT). The PAI, papGII, ibeA, KpsMTIII were exclusive of B2 and D phylogenetic type strains, while sfa/foc, focG, cnf1, hlyA and rfc were exclusively observed among the B2 type strains.The clustering analysis by Rep-PCR distinguished two groups of strains, the first including 96.77% of B2 and D type strains, while the second encompassing 91,5% of A and B1 type strains